Brief: Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
12/01/2026 12:35
Jan 12 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN NUVATION BIO INC - TO RECEIVE UP TO €195 MILLION IN PAYMENTS NUVATION BIO INC - EISAI RECEIVES EXCLUSIVE RIGHTS FOR TALETRECTINIB IN MULTIPLE REGIONS NUVATION BIO INC: MAA FOR TREATMENT OF ADVANCED ROS1+ NSCLC IS EXPECTED TO BE FILED IN EUROPE IN FIRST HALF OF 2026 NUVATION BIO INC - MAA FOR TALETRECTINIB EXPECTED IN EUROPE IN 2026 Source text: ID:nBw7jpqCqa Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth